Causality Assessment

•Download as PPTX, PDF•

2 likes•479 views

Causality assessment is the process of evaluating the relationship between a medical event, such as a disease or adverse drug reaction, and a specific exposure, such as a medication or environmental factor. The purpose of causality assessment is to determine whether the exposure is likely to have caused the event or whether the event is due to other causes. Causality assessment involves a systematic evaluation of the available evidence, including clinical data, laboratory results, medical history, and other relevant information. The assessment is typically based on a set of criteria, such as the temporal relationship between the exposure and the event, the strength of the association, the presence of alternative explanations, and other factors. Causality assessment is an important tool in pharmacovigilance, which is the science of monitoring and evaluating the safety of medicines. It is also used in epidemiological research to identify and understand the causes of diseases and other medical events. Causality assessment is not always straightforward, and there is often a degree of uncertainty involved in the process. However, it is an essential part of evaluating the safety and efficacy of medical treatments and is used by regulatory agencies, healthcare providers, and researchers to make informed decisions about patient care and public health.

What's hot

Med-DRA

Vrajesh Divecha

Comparative observational studies

JSS Collage of Pharmacy, Mysore

This document discusses different types of observational studies used in epidemiology to evaluate adverse events. It describes three major types: cross-sectional studies, case-control studies, and cohort studies. Cross-sectional studies collect data on a population at a single point in time to measure disease prevalence. Case-control studies compare subjects with a disease to controls without the disease to identify risk factors. Cohort studies follow groups over time, some exposed to potential risk factors and some not, to measure relative risk and identify causes.

Active and passive survillance

Ramavath Aruna

This document discusses different methods for drug safety surveillance, including passive and active surveillance. Passive surveillance involves voluntary reporting of adverse drug reactions by healthcare professionals, while active surveillance proactively collects data through methods like monitoring sentinel sites. Other discussed methods include spontaneous reporting, case series, stimulated reporting, medicine event monitoring, registries, cross-sectional studies, case-control studies, cohort studies, and targeted clinical investigations. Large databases and targeted studies can provide important safety information collected through various surveillance techniques.

Methods in causality assessment.pptx

ReshmaManeDeshmukh

Chetan G. Kumbhar's topic discusses methods for assessing causality between drug treatments and adverse reactions or events. There are three main categories of causality assessment methods: 1) expert judgment, which relies on an expert's experience and knowledge; 2) algorithms, which use standardized tools like the Naranjo scale to calculate the likelihood of causation; and 3) probabilistic methods, which use Bayesian statistics to transform prior probabilities into posterior probabilities of drug causation based on epidemiological data and evidence from a particular case. The goal of causality assessment is to determine relationships between drugs and adverse events, detect new safety signals, better understand drug toxicities and benefits, and evaluate adverse drug reaction reports.

Vaccine safety surveillance

Dr Priyanka Goswami

This document discusses vaccine safety surveillance systems. It describes post-marketing surveillance systems like VAERS in the US and EudraVigilance in Europe that monitor adverse events. International organizations like WHO and programs like EPI work to strengthen safety surveillance globally and help low-income countries monitor vaccines. Harmonized reporting systems, guidelines, and data sharing aim to ensure vaccine safety worldwide.

Establishment of Pharmacovigilance Programme

Nipun Gupta

Clinical Trial Safety Monitoring.pptx

DnyanshreeTijare1

Generic drug product development.pptx

Preeti Kulkarni

This document discusses generic drug product development. It defines generic drugs as having the same active ingredients, dosage, strength, quality and performance as brand name drugs. The main goals of generic drugs are to decrease drug prices after patents expire. The generic drug development process involves concept development, system design, detailed design, testing, and production ramp up. It also discusses the legislative history around generic drugs in the US, including the 1984 Hatch-Waxman Act, which established the Abbreviated New Drug Application pathway to expedite generic drug approval.

D&C Act 1940 Schedule Y - A Presentation by Akshay Anand

Akshay Anand

PMS (post marketing surveillance)

SANDEEP LOHMOR

This document discusses post-marketing surveillance (PMS), which refers to monitoring drugs after they have been approved for public use. PMS is important because clinical trials have limitations in terms of patient population size, duration, and ability to detect rare or long-term effects. Sources of PMS information include spontaneous reporting, studies using medical databases, and manufacturer monitoring. Common PMS methods include spontaneous reporting of adverse drug reactions, cohort studies, and case control studies. PMS can help identify new safety issues and provide more information on drug risks and benefits in diverse patient populations.

EUROPEAN MEDICAL AGENCY

datchayani

The European Medicines Agency (EMA) regulates medicines for both human and veterinary use across Europe. Key responsibilities of EMA include evaluating applications for new medicines and monitoring approved medicines. EMA operates through various scientific committees and follows regulatory procedures for clinical trials and marketing authorization applications. EMA helps ensure that medicines available across Europe are safe, effective and of high quality.

Pharmacovigilance signal and signal detection

KiranRajput38

Investigational New Drug Application

Suhas Reddy C

The document discusses Investigational New Drug (IND) applications, which are submitted to the FDA to obtain approval to begin human clinical trials of an experimental drug. An IND application includes preclinical animal data, clinical trial protocols, and information about manufacturing. The FDA has 30 days to review an IND for safety before trials may begin. Clinical holds may be placed on applications that pose unreasonable risks or are missing required information. Notifications are provided to sponsors regarding review outcomes and any deficiencies that must be addressed.

How to report an SAE

Dr. Shweta Bhatia

This document provides guidance on reporting serious adverse events (SAEs) that occur during clinical trials in India. It outlines the key stakeholders involved in SAE reporting, including the investigator, sponsor/CRO, ethics committee, and Drug Controller General of India (DCGI). The timelines and process for initial and follow-up SAE reporting are defined. Requirements for the documents to be submitted in SAE reports, such as the checklist, case report form pages, and discharge summary, are also reviewed to ensure completeness and accuracy of the reports. Common errors made in SAE documentation are highlighted.

Anatomic Therapeutic Chemical Classification, Defined daily dose, Drug utilis...

Dr.Amreen Saba Attariya

institutional review board and independent ethics committee

MOHAMMAD ASIM

The document discusses the role and responsibilities of institutional review boards (IRBs) in protecting human subjects in clinical research. It provides details on: - The composition and quorum requirements of IRBs, including the need for diverse expertise and community representation. - The functions of IRBs, which include reviewing research protocols, approving studies, overseeing informed consent processes, and ensuring ongoing ethical review of approved studies. - The responsibilities of IRBs in evaluating risks and benefits to research participants, assessing payment amounts and methods, and requiring modifications or halting studies when necessary. - The necessary components of informed consent forms used in clinical studies, including study details, risks/benefits, confidentiality

New drug application

Nazmul Hasan Mahmud

The document discusses the three types of New Drug Applications (NDAs) used in the United States to seek FDA approval for new pharmaceutical products. A "full" NDA contains clinical trial data proving safety and efficacy. A 505(b)(2) application relies partly on published information and can potentially save time and money compared to a full application. It is best suited for products representing limited changes to previously approved drugs, like new formulations or indications. An abbreviated application under 505(j) is for generics proving only bioequivalence to an existing drug.

Safety monitoring in clinical trails

GOURIPRIYA L S

Monitoring of clinical trials

kattamurilakshmi

This document discusses clinical trial monitoring. It defines monitoring as overseeing a clinical trial to ensure it follows the protocol, GCP standards, and regulations. The purpose is to protect subject rights and ensure compliance and data quality. Factors like the protocol complexity, site enrollment rate, and performance determine monitoring frequency. Sites are monitored regularly through visits to ensure proper conduct, documentation, and issue resolution. Monitors are trained and qualified by the sponsor to perform monitoring tasks and activities according to a plan.

Post marketing surveillance (PMS)

Shalini Singh

Post-marketing surveillance (PMS) involves monitoring pharmaceutical drugs and medical devices after they have been released to the public to identify adverse drug reactions (ADRs) that were not detected in pre-market clinical trials due to limitations such as narrow study populations and durations. PMS benefits include identifying low frequency ADRs, effects in high risk groups, long term effects, and drug interactions. Information is collected through expert user groups, customer surveys, complaints, literature reviews, and media reports. PMS studies use controlled clinical trials, spontaneous reporting, cohort studies, and case control studies to identify drug effects.

What's hot (20)

Med-DRA

Comparative observational studies

Active and passive survillance

Methods in causality assessment.pptx

Vaccine safety surveillance

Establishment of Pharmacovigilance Programme

Clinical Trial Safety Monitoring.pptx

Generic drug product development.pptx

D&C Act 1940 Schedule Y - A Presentation by Akshay Anand

PMS (post marketing surveillance)

EUROPEAN MEDICAL AGENCY

Pharmacovigilance signal and signal detection

Investigational New Drug Application

How to report an SAE

Anatomic Therapeutic Chemical Classification, Defined daily dose, Drug utilis...

institutional review board and independent ethics committee

New drug application

Safety monitoring in clinical trails

Monitoring of clinical trials

Post marketing surveillance (PMS)

Similar to Causality Assessment

Subject Recruitment in Clinical Trials

Causality Assessment

Related slideshows

More Related Content

What's hot

What's hot (20)

Similar to Causality Assessment

Similar to Causality Assessment (20)

More from ClinosolIndia

More from ClinosolIndia (20)

Recently uploaded

Recently uploaded (20)

Causality Assessment